ENSAIOS CLÍNICOS EM DERMATOLOGIA – PARTE II

Artur César; Alberto Mota; Filomena Azevedo

doi:10.29021/spdv.73.2.364

Artur César Serviço de Dermatologia e Venereologia/Department of Dermatology and Venereology, Centro Hospitalar São João EPE, Porto/Oporto, Portugal; Faculdade de Medicina, Universidade do Porto/Medical School, Oporto University, Portugal
Alberto Mota Serviço de Dermatologia e Venereologia/Department of Dermatology and Venereology, Centro Hospitalar São João EPE, Porto/Oporto, Portugal; Faculdade de Medicina, Universidade do Porto/Medical School, Oporto University, Portugal
Filomena Azevedo Serviço de Dermatologia e Venereologia/Department of Dermatology and Venereology, Centro Hospitalar São João EPE, Porto/Oporto, Portugal

DOI: https://doi.org/10.29021/spdv.73.2.364

Palavras-chave: Ensaios clínicos, Interpretação estatística de dados, Desenho de estudo

Resumo

O crescente número dos ensaios clínicos na área dermatológica exige do dermatologista a capacidade de avaliar a qualidade, compreender, e sintetizar informações de diferentes fontes para decidir sobre as estratégias terapêuticas/ diagnósticas. Este artigo de educação médica contínua aborda os princípios básicos, considerados relevantes e adaptados à área dermatológica, fundamentais na interpretação dos resultados dos ensaios clínicos. A parte II deste artigo aborda os diferentes métodos de análise de dados em ensaios clínicos.

Downloads

Não há dados estatísticos.

Referências

Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;

:238-44.

Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the

ideal method? Is PASI passe? facts and controversies. Clin Dermatol. 2010; 28:67-72.

Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006; 60:984-92.

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004; 140:1513-9.

Townshend AP, Chen CM, Williams HC. How prominent are patient-reported outcomes in clinical trials of dermatological treatments? Br J Dermatol. 2008; 159:1152-9.

Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339-41.

Weiss SC, Rowell R, Krochmal L. Impact of seasonality on conducting clinical studies in dermatology. Clin Dermatol. 2008; 26:565-9.

U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). International Conference of Harmonisation of Pharmaceuticals for Human Use (ICH) E9.

Statistical principles for clinical trials.1998. Disponível em:http://www.fda.gov/cder/guidance/ICH_E9-fnl.pdf.

Alosh M, Fritsch K, Soukup M, Wilkin J. Clinical trials and statistical analyses: what should dermatologists look for in a report? Dermatol Therap. 2009; 22:199-203.

van Lumig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2013; 68:57-63.

Blume J, Peipert JF. What your statistician never told you about P-values. The J Am Assoc Gynecolc Laparosc. 2003;10:439-44.

Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA. Mometasone furoate ointment 0.1% vs. hydrocortisone

ointment 1.0% in psoriasis. Atrophogenic potential. Int J Dermatol. 1989; 28:342-4.

Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multi center, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA.

; 277:1374-9.

Lehr R. Sixteen S-squared over D-squared: a relation for crude sample size estimates. Stat Med. 1992; 11:1099-102.

Bhardwaj SS, Camacho F, Derrow A, Fleischer AB, Jr., Feldman SR. Statistical significance and clinical relevance: the importance of power in clinical trials in dermatology. Arch Dermatol. 2004;140:1520-3.

Zachariae H, Sogaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Dermato-Venereol. 1989; 69:241-4.

Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am AcadDermatol. 1998; 38:478-85.

Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012; 308:2594-604.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemioly. 2010; 63:e1-37.

Revuz J, Moyse D, Poli F, Pawin H, Faure M, Chivot M, et al. A tool to evaluate rapidly the quality of clinical trials on topical acne treatment. Journal of the European Academy of Dermatology and Venereology: J Eur Acad Dermatol Venereol. 2008;22:800-6.

Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323:42-6.